Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease

ClinicalTrials.gov ID: NCT02167256

Public ClinicalTrials.gov record NCT02167256. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2. Moreover, the investigators have recently shown that a specific SFK, namely Fyn, is aberrantly activated by specific conformations of the Amyloid Beta (Aß) peptide from Alzheimer's disease (AD). Genetic deletion of Fyn rescues AD deficits in preclinical models. This clinical trial will test the potential benefit of AZD0530 for Alzheimer's disease modification.

Study identification

NCT ID
NCT02167256
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Yale University
Other
Enrollment
159 participants

Conditions and interventions

Eligibility (public fields only)

Age range
55 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2014 (Actual)
Primary completion
Feb 27, 2018 (Actual)
Completion
Feb 27, 2018 (Actual)
Last update posted
Aug 14, 2019

2014 – 2018

United States locations

U.S. sites
21
U.S. states
17
U.S. cities
20
Facility City State ZIP Site status
Barrow Neurological Institute Phoenix Arizona 85013 —
Banner Sun Health Research Institute Sun City Arizona 85351 —
University of California, Los Angeles Los Angeles California 90095 —
Yale Alzheimer's Disease Research Unit New Haven Connecticut 06510 —
Georgetown University Washington D.C. District of Columbia 20057 —
Wien Center for Clinical Research/Mount Sinai Medical Center Miami Beach Florida 33140 —
University of South Florida - Health Byrd Alzheimer Institute Tampa Florida 33613 —
Northwestern University Chicago Illinois 60611 —
Rush University Medical Center Chicago Illinois 60612 —
Indiana University Indianapolis Indiana 46202 —
University of Iowa Iowa City Iowa 52242 —
University of Kentucky Lexington Kentucky 40504 —
Brigham and Women's Hospital Boston Massachusetts 02115 —
University of Michigan, Ann Arbor Ann Arbor Michigan 48105-2945 —
Mount Sinai School of Medicine New York New York 10029 —
University of Rochester Medical Center Rochester New York 14620 —
Wake Forest University Health Sciences Winston-Salem North Carolina 27157 —
Oregon Health & Science University Portland Oregon 97239 —
University of Pittsburgh, Alzheimer's Disease Research Center Pittsburgh Pennsylvania 15213 —
Roper St. Francis Hospital Charleston South Carolina 29401 —
University of Washington Seattle Washington 98108 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02167256, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 14, 2019 · Synced Oct 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02167256 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →